Biolife solutions stock.

BOTHELL - BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ('CGT') and broader biopharma markets, today announced the launch of Ultraguard, the first ever non-toxic, non-hazardous and non-flammable -70-degreeC phase change material ('PCM'), …Find the latest BioLife Sciences Inc. (BLFE) stock quote, history, news and other vital information to help you with your stock trading and investing.Culture supplement to replace FBS or AB Serum. Biodefined composition reduces lot-to-lot variability. Supports a wide range of cell types including MSCs, T-Cells, NK Cells, Endothelial cells, and more. Promotes improved in vitro and In vivo cell quality in CAR-T applications. Typically used at concentrations ranging from 2% to 10%.BioLife Solutions Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 24, 2023 4:04 p.m. EST Delayed quote $ 14.00 -0.08 -0.57% After Hours Volume: 1.96K …Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.See BioLife Solutions, Inc. (BLFS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

Aug 9, 2022 · BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ...

BioLife Solutions (NASDAQ:BLFS) and Zynex (NASDAQ:ZYXI) are both small-cap medical companies, but which is the superior stock?We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership, media sentiment and community ranking.Mar 23, 2023 · BioLife Solutions Reports Third Quarter 2023 Financial Results. BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene... Nov 02, 2023. Supplier: BIOLIFE SOLUTIONS INC 210373. This item has a minimum qty of 4 per supplier requirements. The CryoStor series of cell-specific, optimized freeze media, is designed to prepare and preserve cells in ultra low temperature environments (-70C to -196C). CryoStor CS10, pre-formulated with 10% DMSO, provides a safe, protective environment ...10 Mar, 2023, 15:38 ET. BOTHELL, Wash., March 10, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS ), a leading supplier of class-defining bioproduction tools and services for the cell ...

msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM.

The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.

Aug 11, 2023 · Shares of BioLife Solutions (BLFS 7.11%) were down more than 37% for the week, as of 3:15 p.m. ET on Friday, ... The healthcare company's stock closed last week at $19.22, then dropped to a 52 ... BioLife Solutions Inc (ISIN: US09062W2044, WKN: A1XCF2): ✓ Precio Acciones BioLife Solutions Inc ✓ Rendimiento de Dividendos y Fechas, ✓ News ✓ Plan de ...The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.References throughout this Form 10-K to “BioLife Solutions, Inc. ... Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report, before deciding to invest in our common stock. ...BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...BioLife Solutions: Overcoming Challenges and Primed for Growth – An Optimistic Buy Recommendation Amid Revenue Surpassing Expectations and Anticipated Divestiture

In today’s fast-paced world, it can be challenging to stay organized and manage our time effectively. With so many tasks and responsibilities vying for our attention, it’s crucial to have a reliable tool that can help us stay on track. This...BioLife will issue 6,646,870 shares of common stock for 100% of the outstanding shares of Stirling in an all-stock transaction, which is expected to close early in the second quarter of 2021. With Stirling, BioLife believes that total GAAP revenue in 2021 will exceed $100 million and the transaction is expected to be accretive on an adjusted ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.Discover more Overcome the challenges of cell expansion and product preservation throughout CGT processing. Independent research demonstrates the medium and material used in sample cryopreservation impacts biologic viability. Formulation must be sterile, free from adventitious agents and qualified before use to remove susceptibility from batch-to …Dec 1, 2023 · msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM. Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.

BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting ...

The stock lies in the middle of a very wide and strong rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 10.89% during the next 3 months and, with a 90% probability hold a price between $0.00000328 and $0.0002 at the end of this 3-month period.BioLife Solutions is trading near 52-week lows as its growth story has floundered and profitability remains uncertain. Learn why I rate BLFS stock a hold.Chg %. Market Cap. Evogene Ltd. -0.32%. $32.76M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …BOTHELL, Wash., Jan. 5, 2021 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction ...BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced ...BioLife Solutions Trading Up 2.5 %. NASDAQ BLFS traded up $0.33 on Monday, hitting $13.58. 44,504 shares of the stock were exchanged, compared to its average volume of 403,529. The company’s 50 ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Biolife Solutions share forecasts, stock quote and buy / sell signals below. According to present data Biolife Solutions's BLFS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.CryoStor®CS10 effectively mitigates temperature-induced molecular cell stress responses to maximize post-thaw viability and recovery for a variety of immune cell types, including T cells (data not shown) and B cells. Here, human B cells from 6 different donors cryopreserved in CryoStor®CS10 show reproducibly high viability after thawing, as ...BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.

May 10, 2023 · BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ...

Mar 13, 2023 · BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...

BioLife Solutions is reaffirming 2023 revenue guidance, which is based on expectations for its existing business. Total revenue for 2023 is expected to range from $188 million to $202 million ...May 10, 2023 · BioLife Solutions Reports First Quarter 2023 Financial Results. Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28%. Q1 2023 ... On average, Wall Street analysts predict. that Biolife Solutions's share price could reach $25.50 by Aug 10, 2024. The average Biolife Solutions stock price prediction forecasts a potential upside of 103.84% from the current BLFS share price of $12.51. Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Get in touch. BioLife Solutions Inc. 3303 Monte Villa Parkway, Suite 310, Bothell , WA 98021 USA. For assistance, please call us Monday through Friday (9:00 am to 5:00 pm PST) at:BioLife Solutions Inc stock performance at a glance. Check BioLife Solutions Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. Multiple Uses for CryoStor in Cell Manufacturing Journal articles recently added to BioLife Solutions’ Evidence Library illustrate several stages during the cell manufacturing process for which CryoStor CS10® cryopreservation solution is applicable. The three articles that follow include several different cell types cryopreserved in …BioLife issued 6,646,870 shares of common stock in exchange for 100% of the outstanding shares of Stirling. BioLife management has provided guidance for Stirling's 2021 post-closing revenue contribution to be $35 million to $37 million , with total 2021 revenue of $101 million to $110 million .The business earned $33.33 million during the quarter, compared to the consensus estimate of $33.28 million. BioLife Solutions has generated ($2.37) earnings per share over the last year (($2.37) diluted earnings per share). Earnings for BioLife Solutions are expected to grow in the coming year, from ($1.06) to ($0.26) per share.BioLife Solutions Trading Up 2.5 %. NASDAQ BLFS traded up $0.33 on Monday, hitting $13.58. 44,504 shares of the stock were exchanged, compared to its average volume of 403,529. The company’s 50 ...20 sept 2022 ... About BioLife Solutions Stock ... Today, BioLife has a market cap of just over $1 billion, with total revenue of $119.2 million in 2021, an ...According to the issued ratings of 5 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 5 buy ratings for BLFS. The average twelve-month price prediction for BioLife Solutions is $24.60 with a high price target of $28.00 and a low price target of $22.00. Learn more on BLFS's analyst rating ...

Biolife Solutions will release earnings for Q1 on May 10. Wall Street predict expect Biolife Solutions will release losses per share of $0.213. Go here to watch Biolife Solutions stock price in ...BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) shares fell 4.2% during trading on Monday . The company traded as low as $13.37 and last traded at $13.49. 76,840 shares changed hands ...BioLife Solutions Stock Performance. BLFS stock opened at $14.08 on Monday. The business has a 50 day moving average of $12.13 and a 200-day moving average of $16.47. BioLife Solutions, Inc. has a 12-month low of $8.92 and a 12-month high of $26.89. The firm has a market cap of $619.96 million, a PE ratio of -5.94 and a beta of 1.57.BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days. BioLife’s relationship with SAVSU …Instagram:https://instagram. mutual funds with highest dividendssportsman's warehouse stockmmp stock dividendstart engine investment Mar 22, 2021 · Athens, Ohio, March 22, 2021 — Stirling Ultracold, a privately-held innovative developer and manufacturer of ultra-low temperature (ULT) freezers, today announced it has signed a definitive agreement to merge into BioLife Solutions (NASDAQ: BLFS) to combine expertise and expand individual product offerings for biopharma research and life ... BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately. qqq graphvht stocks The current stock price of is . Chart and price action Where to buy Biolife Solutions shares? Does not pay dividends in 2023. Prediction and analyst recommendations. how much does medicaid pay for braces Nov 16, 2023 · Headquartered in Bothell, Washington, BioLife Solutions, Inc. (NASDAQ:BLFS) is a bioproduction tools and services provider. On November 15, 2023, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed ... Hedge fund activity in BioLife Solutions, Inc. (NASDAQ:BLFS) Heading into the second quarter of 2020, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of ...Nov 17, 2023 · Open 18.44. Day High 18.95. Day Low 18.17. Prev Close 18.25. 52 Week High 26.96. 52 Week High Date 09/08/22. 52 Week Low 10.40. 52 Week Low Date 05/12/22. Market Cap 812.385M.